Is It Too Late To Consider AstraZeneca (LSE:AZN) After Strong Multi‑Year Share Gains?

Simply Wall St

Tue, February 17, 2026 at 3:11 PM GMT+9 6 min read

In this article:

AZN

+0.50%

Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.

If you are wondering whether AstraZeneca's share price still offers value or is starting to look expensive, the next sections will walk through what the current market price might be implying.

AstraZeneca's shares last closed at £151.60, with returns of 9.2% over 7 days, 7.9% over 30 days, 11.5% year to date, 32.2% over 1 year, 40.0% over 3 years and 136.3% over 5 years. This gives helpful context before looking at valuation.

Recent news coverage has largely focused on AstraZeneca's position as a major pharmaceuticals group and ongoing interest in its wider pipeline and portfolio. This helps explain why many investors keep a close eye on the share price. Commentators often point to how sentiment around large healthcare companies can shift quickly as trial data, regulatory decisions or product updates emerge.

On Simply Wall St's 6 point valuation checklist, AstraZeneca currently scores 3 out of 6. We will next look at what different valuation methods say about that score, before finishing with a broader way to think about what the market is really pricing in.

AstraZeneca delivered 32.2% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry.

Approach 1: AstraZeneca Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company might be worth today by projecting its future cash flows and discounting them back to a present value.

For AstraZeneca, Simply Wall St uses a 2 Stage Free Cash Flow to Equity model, based on cash flows reported in US$. The latest twelve month free cash flow is about US$9.5b. Analyst projections and subsequent extrapolations suggest free cash flow of around US$20.2b in 2030, with interim annual figures between 2026 and 2035 ranging from roughly US$10.9b to US$27.1b before discounting.

After discounting these projected cash flows, the model arrives at an estimated intrinsic value of US$228.28 per share. Compared with the current share price of £151.60, this implies AstraZeneca is trading at a 33.6% discount to that DCF estimate, which indicates that the shares may be undervalued on this measure.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests AstraZeneca is undervalued by 33.6%. Track this in your watchlist or portfolio, or discover 8 more high quality undervalued stocks.

AZN Discounted Cash Flow as at Feb 2026

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for AstraZeneca.

Approach 2: AstraZeneca Price vs Earnings (P/E)

For a profitable company like AstraZeneca, the P/E ratio is a useful yardstick because it links what you pay for the shares to the earnings the business is already generating.

Story continues  

In simple terms, higher expected growth and lower perceived risk usually justify a higher, or more generous, P/E multiple, while lower growth expectations or higher risk tend to line up with a lower, or more cautious, P/E.

AstraZeneca currently trades on a P/E of 31.34x. That is above the Pharmaceuticals industry average of 21.97x and also above the broader peer group average of 14.31x, which indicates the market is already attaching a premium to its earnings.

Simply Wall St’s Fair Ratio metric estimates what a more tailored P/E might look like, given AstraZeneca’s earnings growth profile, profit margins, industry, market cap and risk factors. This tends to be a more specific guide than a simple comparison with peers or the sector, because it adjusts for company level characteristics rather than assuming all firms should trade on the same multiple.

Here, the Fair Ratio for AstraZeneca is 33.13x, which is slightly above the current 31.34x. On this basis, the shares appear somewhat cheap relative to that Fair Ratio estimate.

Result: UNDERVALUED

LSE:AZN P/E Ratio as at Feb 2026

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 4 top founder-led companies.

Upgrade Your Decision Making: Choose your AstraZeneca Narrative

Earlier we mentioned that there is an even better way to understand valuation. On Simply Wall St you can use Narratives, which let you set out your own story for AstraZeneca, link that story to specific assumptions about future revenue, earnings and margins, and then see the Fair Value that results from those numbers. This is all available within an easy tool on the Community page that updates as new news or earnings arrive and lets you compare different views. For example, you can look at a higher Fair Value of about £182.81 that reflects a more optimistic view on oncology and 2030 sales ambitions, or a lower Fair Value of about £108.53 that reflects more caution on drug pricing, patent expiries and execution risk, and then decide for yourself how those Fair Values stack up against the current share price.

For AstraZeneca, however, we will make it really easy for you with previews of two leading AstraZeneca Narratives:

First up is a more optimistic take that leans into the strength of the pipeline and long term earnings power.

🐂 AstraZeneca Bull Case

Fair value: £152.79

Implied discount to this fair value: 0.8% relative to the last close of £151.60

Revenue growth assumption: 5.77% a year

Analysts in this camp see a strong late stage pipeline in oncology, rare diseases and cardiovascular or metabolic therapies, with management pointing to more than US$10b of potential peak risk adjusted revenue from new medicines.

They factor in ongoing expansion in emerging markets such as China, Latin America and Southeast Asia, together with investments in technologies like ADCs, bispecific antibodies and mRNA platforms, which are expected to support higher margins and earnings resilience.

Key risks they highlight include exposure to price controls, biosimilar competition and heavy dependence on a handful of blockbuster drugs, plus the chance that high R&D spend does not consistently translate into productive launches.

Now compare that with a more cautious view that leans harder on drug pricing pressure and patent expiries.

🐻 AstraZeneca Bear Case

Fair value: £108.53

Implied premium to this fair value: 39.7% relative to the last close of £151.60

Revenue growth assumption: 3.50% a year

This narrative focuses on tighter global controls on drug pricing and reimbursement, with concerns that this could cap revenue growth and squeeze margins as more of AstraZeneca's portfolio targets chronic conditions.

It puts more weight on upcoming patent expiries for drugs like Tagrisso, Farxiga and Imfinzi, with the view that biosimilar and generic competition could erode high margin revenue streams and lower returns later on.

It also flags execution and geopolitical risk, pointing to heavy ongoing R&D and manufacturing investment, expansion into higher risk markets and the potential impact of policy shifts, tariffs or supply chain disruption on long term earnings and cash flow stability.

Taken together, these two narratives show you how different assumptions about pricing, patents, growth and execution can lead to very different views on fair value, even when they start from the same set of public information.

Do you think there’s more to the story for AstraZeneca? Head over to our Community to see what others are saying!

LSE:AZN 1-Year Stock Price Chart

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include AZN.L.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info